Frilling A, Åkerström G, Falconi M, Pavel M, Ramos J, Kidd M, Modlin IM (2012) Neuroendocrine tumor disease: an evolving landscape. Endocr Relat Cancer 19:163–185. https://doi.org/10.1530/ERC-12-0024
Scandurra C, Modica R, Maldonato NM, Dolce P, Dipietrangelo GG, Centello R, di Vito V, Bottiglieri F, de Cicco F, Giannetta E, Isidori AM, Lenzi A, Muzii B, Faggiano A, Colao A (2021) Quality of life in patients with neuroendocrine neoplasms: the role of severity, clinical heterogeneity, and resilience. J Clin Endocrinol Metab 106:e316–e327. https://doi.org/10.1210/clinem/dgaa760
Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC (2017) Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 3:1335–1342. https://doi.org/10.1001/jamaoncol.2017.0589
Article PubMed PubMed Central Google Scholar
Das S, Dasari A (2021) Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences? Curr Oncol Rep 23:43. https://doi.org/10.1007/s11912-021-01029-7
Article PubMed PubMed Central Google Scholar
Faggiano A, lo Calzo F, Pizza G, Modica R, Colao A, (2017) The safety of available treatments options for neuroendocrine tumors. Expert Opin Drug Saf 16:1149–1161. https://doi.org/10.1080/14740338.2017.1354984
CAS Article PubMed Google Scholar
Faggiano A, di Maio S, Mocerino C, Ottaviano M, de Divitiis C, Guarnotta V, Dolce P, Modica R, Puliafito I, Tozzi L, di Sarno A, Leo S, Riccardi F, Palmieri G, Tafuto S, Bianco A, Badalamenti G, Colao A (2019) Therapeutic sequences in patients with grade 1–2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group. Endocrine 66:417–424. https://doi.org/10.1007/s12020-019-01894-0
CAS Article PubMed Google Scholar
Beesley VL, Burge M, Dumbrava M, Callum J, Neale RE, Wyld DK (2018) Perceptions of care and patient-reported outcomes in people living with neuroendocrine tumours. Supp Care Cancer 26:3153–3161. https://doi.org/10.1007/s00520-018-4166-5
Firkins J, Hansen L, Driessnack M, Dieckmann N (2020) Quality of life in “chronic” cancer survivors: a meta-analysis. J Cancer Surviv 14:504–517. https://doi.org/10.1007/s11764-020-00869-9
Jiménez-Fonseca P, Carmona-Bayonas A, Martín-Pérez E, Crespo G, Serrano R, Llanos M, Villabona C, García-Carbonero R, Aller J, Capdevila J, Grande E (2015) Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors. Cancer Metastasis Rev 34:381–400. https://doi.org/10.1007/s10555-015-9573-1
CAS Article PubMed Google Scholar
Haugland T, Devon HA (2019) Symptoms, psychosocial factors, and health-related quality of life in patients with neuroendocrine tumors: An integrative review. Cancer Nurs 42:E36–E46. https://doi.org/10.1097/NCC.0000000000000614
White BE, Druce MR, Grozinsky-Glasberg S, Srirajaskanthan R, Gamper EM, Gray D, Mujica-Mota R, Ramage JK (2020) Health-related quality of life in neuroendocrine neoplasia: a critical review. Endocr Relat Cancer 27:R267–R280. https://doi.org/10.1530/ERC-20-0066
CAS Article PubMed Google Scholar
Martini C, Gamper EM, Wintner L, Nilica B, Sperner-Unterweger B, Holzner B, Virgolini I (2016) Systematic review reveals lack of quality in reporting health-related quality of life in patients with gastroenteropancreatic neuroendocrine tumours. Health Qual Life Outcomes 14:127. https://doi.org/10.1186/s12955-016-0527-2
Article PubMed PubMed Central Google Scholar
Hallet J, Davis LE, Mahar AL, Isenberg-Grzeda E, Bubis LD, Myrehaug S, Zhao H, Beyfuss K, Moody L, Law CHL, Coburn NG (2019) Symptom burden at the end of life for neuroendocrine tumors: an analysis of 2579 prospectively collected patient-reported outcomes. Ann Surg Oncol 26:2711–2721. https://doi.org/10.1245/s10434-019-07441-5
Martini C, Buxbaum S, Rodrigues M, Nilica B, Scarpa L, Holzner B, Virgolini I, Gamper EM (2018) Quality of life in patients with metastatic gastroenteropancreatic neuroendocrine tumors receiving peptide receptor radionuclide therapy: information from a monitoring program in clinical routine. J Nucl Med 59:1566–1573. https://doi.org/10.2967/jnumed.117.204834
CAS Article PubMed Google Scholar
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, Haes JCJMD, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F (1993) The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376. https://doi.org/10.1093/jnci/85.5.365
CAS Article PubMed Google Scholar
Hjemdal O, Friborg O, Braun S, Kempenaers C, Linkowski P, Fossion P (2011) The resilience scale for adults: construct validity and measurement in a Belgian sample. Int J Test 11:53–70. https://doi.org/10.1080/15305058.2010.508570
Bates D, Mächler M, Bolker BM, Walker SC (2015) Fitting linear mixed-effects models using lme4. J Stat Softw 67:1–48
Eicher M, Matzka M, Dubey C, White K (2015) Resilience in adult cancer care: an integrative literature review. Oncol Nurs Forum 42:E3-16. https://doi.org/10.1188/15.ONF.E3-E16
Matzka M, Mayer H, Köck-Hódi S, Moses-Passini C, Dubey C, Jahn P, Schneeweiss S, Eicher M (2016) Relationship between resilience, psychological distress and physical activity in cancer patients: a cross-sectional observation study. PLoS ONE 11:e0154496. https://doi.org/10.1371/journal.pone.0154496
CAS Article PubMed PubMed Central Google Scholar
Ristevska-Dimitrovska G, Filov I, Rajchanovska D, Stefanovski P, Dejanova B (2015) Resilience and quality of life in breast cancer patients. Open Access Maced J Med Sci 3:727–731. https://doi.org/10.3889/oamjms.2015.128
Article PubMed PubMed Central Google Scholar
Clarke G, Asiedu YA, Herd K, Sharma S (2019) Exploring the relation between patients’ resilience and quality of life after treatment for cancer of the head and neck. Br J Oral Maxillofac Surg 57:1044–1048. https://doi.org/10.1016/j.bjoms.2019.09.007
CAS Article PubMed Google Scholar
Li X, Chen S, Zhang J, Li L, Li Y, Ye M (2021) Resilience process and its protective factors in long-term survivors after lung cancer surgery: a qualitative study. Supp Care Cancer 29:1455–1463. https://doi.org/10.1007/s00520-020-05633-4
Thong MSY, van Noorden CJF, Steindorf K, Arndt V (2020) Cancer-related fatigue: Causes and current treatment options. Curr Treat Options Oncol 21:17. https://doi.org/10.1007/s11864-020-0707-5
Article PubMed PubMed Central Google Scholar
Pearman TP, Beaumont JL, Cella D, Neary MP, Yao J (2016) Health-related quality of life in patients with neuroendocrine tumors: an investigation of treatment type, disease status, and symptom burden. Supp Care Cancer 24:3695–3703. https://doi.org/10.1007/s00520-016-3189-z
Walter T (2017) Maintaining quality of life for patients with neuroendocrine tumours. Lancet Oncol 18:1299–1300. https://doi.org/10.1016/S1470-2045(17)30618-6
Faggiano A, Modica R, Calzo F, Camera L, Napolitano V, Altieri B, de Cicco F, Bottiglieri F, Sesti F, Badalamenti G, Isidori AM, Colao A (2019) Lanreotide therapy vs active surveillance in MEN1-related pancreatic neuroendocrine tumors 2 centimeters. J Clin Endocrinol Metab 105:007
Rossi R, Jannini TB, Socci V, Pacitti F, Lorenzo G (2021) Stressful life events and resilience during the COVID-19 lockdown measures in Italy: Association with mental health outcomes and age. Front Psychiatry 12:635832. https://doi.org/10.3389/fpsyt.2021.635832
Article PubMed PubMed Central Google Scholar
Panzuto F, Maccauro M, Campana D, Faggiano A, Massironi S, Pusceddu S, Spada F, Ferone D, Modica R, Grana CM, Ferolla P, Rinzivillo M, Badalamenti G, Zatelli MC, Gelsomino F, de Carlo E, Bartolomei M, Brizzi MP, Cingarlini S, Versari A, Fanciulli G, Arvat E, Merola E, Cives M, Tafuto S, Baldari S, Falconi M (2021) Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet). J Endocrinol Investig 44:989–994. https://doi.org/10.1007/s40618-020-01393-4
Massironi S, Campana D, Pusceddu S, Albertelli M, Faggiano A, Panzuto F, Smiroldo V, Andreasi V, Rossi RE, Maggio I, Torchio M, Dotto A, Modica R, Rinzivillo M, Carnaghi C, Partelli S, Fanetti I, Lamberti G, Corti F, Ferone D, Colao A, Annibale B, Invernizzi P, Falconi M, ItaNet (Italian Association for Neuroendocrine Tumours) (2021) Study Group. Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: Data from a retrospective multi-centric study. Dig Liver Dis 53:367–374. https://doi.org/10.1016/j.dld.2020.09.031
留言 (0)